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Summary Overexpression of p53 correlates with neoplasia in many cytological specimens. To test the specificity of overexpressed p53 as a
tumour marker for the detection of pancreatic cancer, we analysed cytological specimens of pancreatic juice samples from patients with
pancreatitis or pancreatic carcinoma (n = 42) for p53 protein overexpression. p53 protein overexpression was found in 59% of patients with
pancreatitis and 67% of patients with pancreatic carcinoma. Thus, the assessment of p53 protein overexpression is not useful in the diagnosis
of pancreatic cancer. Overexpressed p53 during pancreatitis appears to be wild-type p53. Overexpression of p53 may result from DNA
damage occurring during chronic inflammation. It is well established that p53 can induce apoptosis upon DNA damage. Consequently, we
found apoptotic cell death in five out of five tested cytological preparations from patients with pancreatitis as well as in one out of one
pancreatic carcinoma specimen.
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In recent years, our knowledge of the molecular pathogenesis of
pancreatic cancer has greatly increased. At least 75% ofpancreatic
carcinomas have mutations in codon 12 of the Ki-RAS oncogene
(Almoguera et al, 1988; Shibata et al, 1990; Kalthoff et al, 1993),
and more than 50% of pancreatic carcinomas express an altered
p53 tumour-suppressor gene (Barton et al, 1991; Kalthoff et al,
1993). Deletions of cyclin kinase inhibitors pl6/MTS1 (Caldas
et al, 1994) and pl5/MTS2 (Naumann et al, 1996) have been
described, and a new tumour-suppressor gene, DPC4, has been
found very recently (Hahn et al, 1996). In spite ofthis progress at
the molecular level, the clinical outcome of patients with pancre-
atic cancer is still very poor. Thus, detection of early stages of
pancreatic cancer is still crucial for a better prognosis.
For many cytological specimens, the detection of p53 over-
expression by immunocytochemistry strongly correlates with
neoplasia (Dowell et al, 1994). Our aim was to establish whether
the detection ofp53 overexpression in cytological specimens from
pancreatic juice samples, collected during ERCP (endoscopic
retrograde cholangiopancreaticography), may be useful in
detecting early stages ofpancreatic carcinoma.
p53 protein overexpression was detected in nearly 60% ofcyto-
logical specimens from patients with pancreatitis but without any
sign ofpancreatic cancerforup to 5 years (median follow-up) after
ERCP. This indicates that, in the case of pancreatic disease, p53
protein overexpression does notcorrelate with neoplasia. However
p53 seems to play an important role during pancreatitis, as
apoptotic cell death has been observed during chronic disease.
This is in line with the function ofp53 as an inductor ofapoptotic
cell death (Lane, 1992).
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MATERIALS AND METHODS
Preparation of cytological specimens by cytospin of
pancreatic juice
Pancreatic juice samples were collected during diagnostic ERCP
from a total of 42 patients. One group comprised 27 patients
suffering from chronic pancreatitis. The other group had 15
patients with pancreatic ductal adenocarcinomas, the vast majority
of which were in stage II and III. Sample preparation was
performed exactly as described previously (Schmiegel et al, 1990).
Median follow-up was 5 years in the group ofpancreatitis patients.
During this period, no pancreatic cancer cases were observed.
Antibodies and immunoperoxidase studies
The p53-specific monoclonal antibodies PAbl801, PAb240 and
PAbl620 were obtained from Oncogene Sciences (Dianova,
Hamburg). The polyclonal antiserum against recombinant
human p53 (CM-1) was purchased from Medac (Hamburg).
Immunoperoxidase studies were performed exactly as described
previously (Kalthoff et al, 1993). Samples were scored positive
when at least 5% of the cells from the investigated cytospin were
positively stained. Because of limitations in the yield of cyto-
logical specimens, we were not able to test all patients' samples
with the entire panel ofantibodies in parallel.
In situ detection of apoptotic cell death
DNA fragmentation was detected by the terminal transferase-
mediated dUTP-biotin nick end labelling reaction (TUNEL),
modified for cell culture conditions (Gavrieli et al, 1992).
Briefly, the cytological specimens were fixed in acetone for
10 min, then rinsed in Tris-acetate buffer (0.1 M Tris-acetate,
pH 7.2). Twenty microlitres of the reaction mixture [15 ,ul of
water, 4 ,ul of cobalt chloride buffer (Boehringer, Mannheim),
2 ,ul of biotin 16-dUTP (equal to 16 fmol) (Boehringer,
Mannheim) and 10 units of TdT (Boehringer, Mannheim)] were
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Table 1 Summary of immunoperoxidase staining of pancreatic juice samples
from patients with pancreatitis or pancreatic cancer with diverse antibodies
Pancreatitis Pancreatic carcinoma
Positive staining with at 16/27 (59%) 10/15 (67%)
least one antibody
PAb 1801 6/11 (54%) 2/3 (66%)
CM-1 13/22 (59%) 10/15 (66%)
PAb240 6/21 (28%) 3/11 (27%)
Pabl620 11/27 (40%) 10/13 (76%)
Cytospins of pancreatic juice samples from patients with pancreatitis or
pancreatic cancer were analysed by immunoperoxidase staining with diverse
antibodies.
added and incubated for 40 min at 37°C in a humit chamber.
After stopping the reaction and washing the samples in phos-
phate-buffered saline (PBS), the slides were incubated with a
1:500 dilution of streptavidin-conjugated Cy3 fluorescence dye
(Dianova, Hamburg). Acetone-fixed cells grown in cell culture
were always used as a negative control.
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RESULTS
Detection of p53 expression in cytological specimens
of pancreatic juice from patients with pancreatic
carcinoma or pancreatitis
Cytological specimens were analysed with a panel ofp53-specific
antibodies. Sixteen out of twenty-seven (59%) specimens from
patients with pancreatitis and 10 out of 15 (66%) specimens from
patients with pancreatic carcinoma were positive for p53 protein
expression with at least one out of four p53-specific antibodies
(summarized in Table 1). The majority of cytological specimens
(n = 27) were analysed with the antibody PAb162O. Eleven out of
twenty-seven (40%) specimens from patients with pancreatitis and
10 out of 13 (76%) specimens frompatients withpancreatic cancer
were positive for PAb1620 (Table 1). Figure 1 shows typical
immunoperoxidase staining patterns of pancreatic juice samples
from a patient with pancreatitis.
Apoptotic cell death detected on cytological specimens
Cytological specimens of pancreatic juice from patients with
pancreatitis were analysed for apoptotic cell death in situ using the
r-
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Figure 1 Immunoperoxidase staining of cytological specimens from a patient with pancreatitis. Cytological specimens from a patient with pancreatitis were
analysed with a panel of antibodies: negative control (A), DO-7 (B), CM-1 (C) and PAbl620 (D)
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Figure 2 In situ detection of apoptotic cell death. Cytological specimens from
patients with pancreatitis were tested for apoptotic cell death with the TUNEL
reaction as described in Material and methods
TUNEL reaction. The TUNEL reaction detects DNA strand breaks
- hallmarks of apoptotic cell death - in fixed specimens (Gavrieli
et al, 1992).
Five out of five analysed specimens from patients with pancre-
atitis and one out of one with pancreatic adenocarcinoma were
positive for the TUNEL reaction, and a typical fluorescence
pattern is shown in Figure 2.
DISCUSSION
The prognosis ofpatients with pancreatic cancer depends critically
on the time of diagnosis, as curative surgery is successful only if
performed in the early stages of disease.
Two epidemiological studies have shown an enhanced risk of
developing pancreatic cancer in patients with chronic pancreatitis
(Lowenfels et al, 1993; Ekbom et al, 1994). This implies that a
certain group of patients with clinical signs of chronic pancreatitis
at the time of examination may already have developed an early
stage of pancreatic carcinoma.
For many cytological specimens, a strong correlation exists
between the detection of p53 overexpression, as demonstrated by
immunofluorescence in diverse cytological specimens (urine,
sputum, bronchial lavage, ovarian cyst fluids, pleural and peri-
toneal aspirates, fine-needle aspirations from visceral sites and
tissue imprints) and in neoplasia (Dowell et al, 1994).
Our aim was to establish whether the detection of p53 protein
overexpression in cytological specimens of pancreatic juice
samples, collected during ERCP, may be useful in the early diag-
nosis of pancreatic cancer.
Almost 60% of cytological specimens tested from patients with
pancreatitis showed an overexpression of p53 protein. The assess-
ment ofp53 overexpression in pancreatic juice samples is therefore
not useful for tumour diagnosis. Further investigation will show
whether DNA sequencing of thep53 gene will be more suitable.
The detection of p53 protein overexpression in cytological spec-
imens ofpancreatic juice samples raises the question ofthe role that
p53 may play during pancreatitis. p53 was detectable with the anti-
body PAb1620 in 40% of cytological specimens from patients with
pancreatitis. In our hands, PAb1620 was specific for wild-type p53
overexpression. Tumour cell lines expressing even high amounts
of mutated p53 were consistently negative for staining with
PAb1620 in contrast to the SV80 tumour cell line, which expresses
wild-type p53 and was positive for PAbl620 under the very same
immunostaining conditions (Kalthoff et al, 1993). During pancre-
atitis, overexpressed p53 may therefore be wild-type p53 and not
mutated p53. This is in line with the clinical follow-up ofpatients
in whom no signs ofpancreatic cancerwere observed. The positive
results with the PAb1620 staining ofpancreaticjuice samples from
patients with pancreatic cancer can be explained in two ways.
PAbl620 may detect mutated p53 in wild-type conformation in
tumour cells. The other explanation is that as a result ofinflamma-
tion during pancreatic carcinoma non-transformed cells of the
pancreatic duct may die by apoptotic cell death, which is accompa-
nied by wild-type p53 overexpression. We favour the latter expla-
nation because we do not expect that almost 80% of analysed
samples from patients with pancreatic cancer express mutated p53
that has a wild-type conformation. It can be concluded from the
results shown in Table 1 that the overall detection rate of the
various antibodies that either react with wild-type and mutated p53
(Pab 1801, CM-1) or preferentially with mut p53 (Pab 240) or
selectively with wild-type p53 (Pab 1620) is of the same order of
magnitude in the specimens from both groups of patients. The
somewhat higher detection rate obtained by Pab 1620 in the
pancreatic cancer group may be related to the rather low number of
specimens tested.
A very important role of wild-type p53 as a 'guardian of the
genome' (Lane, 1992) is its ability to induce apoptosis upon DNA
damage. For example p53 is up-regulated upon UV radiation of
skin (Hall et al, 1993). During chronic inflammation, DNA
damage is likely to occur through oxygen and nitric oxide radicals,
which are known to be potent DNA-damaging agents. In addition,
a direct redox modulation of p53 conformation has been described
(Hainaut et al, 1993). Furthermore, TNF-a, as a central mediator
of inflammation, is able to induce apoptotic cell death and to up-
regulate p53 protein expression in pancreatic cancer cell lines
expressing wild-type p53 in vitro (data not shown).
Thus, p53 protein overexpression detected in cells of pancreatic
juice samples from patients with pancreatitis or pancreatic cancer
could be the result of DNA damage or TNF-a exposure during
inflammation. Wild-type p53 protein overexpression would then be
expected to lead to apoptotic cell death. Consequently we asked
whether apoptotic cell death might be manifested in the cytological
specimens from patients with pancreatitis or pancreatic cancer. This
was in fact the case in six out of six tested cytological specimens.
The detection of p53 overexpression during pancreatitis corre-
lates with the observation that antibodies against recombinant p53
are detectable in serum samples from patients with pancreatitis
(Marxsen et al, 1994). Chronic pancreatitis is one ofthe rare exam-
ples in which antibodies to p53 are detectable during inflammation
and in which p53 overexpression is observed.
Recently, Tada et al (1996) showed that Ki-RAS mutations
occur in hyperplastic foci of the pancreatic duct, even when no
pancreatic cancer or pancreatitis was demonstrable. Thus, muta-
tion of Ki-RAS on its own cannot lead to pancreatic cancer - other
genetic alterations have to occur.
Inflammatory processes during chronic pancreatitis can be
expected to damage DNA. As our results suggest, this may result
in p53 protein overexpression and apoptotic cell death. In some
patients, a p53 mutation may occur during inflammation,
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reflecting another step in the carcinogenesis of pancreatic cancer.
It will be ofinterest to establish whether patients with a history of
pancreatic carcinoma and pancreatitis have a higher degree ofp53
mutation than patients without a history ofpancreatitis.
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